We can’t show the full text here under this license. Use the link below to read it at the source.
Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double‐blind, placebo‐controlled, phase 3 trial (SYNCHRONIZE ™‐1)
Survodutide for obesity treatment: Participant characteristics in a late-stage placebo-controlled trial
AI simplified
Abstract
Participants in the SYNCHRONIZE-1 trial had a mean age of 47.1 years and a BMI of 37.9 kg/m².
- A total of 725 individuals from 14 countries were enrolled, with 59.4% identifying as female.
- complications among participants included hypertension in 40.0%, dyslipidaemia in 33.7%, and prediabetes in 30.2%.
- Baseline measurements indicated a mean waist circumference of 115.2 cm and a mean haemoglobin A1c of 5.5%.
- 47.3% of participants were from North America, 21.0% from Europe, and 20.0% from East Asia.
- 21.8% of participants reported taking lipid-lowering medications.
AI simplified
Key numbers
47.1 years
Mean Age of Participants
Mean age of 725 randomized participants
37.9 kg/m²
Mean BMI of Participants
Mean BMI of 725 randomized participants
59.4%
Percentage of Female Participants
Percentage of 725 randomized participants